Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jan 1;1(2):124-33.

Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia

Brian A Webber  1 , Melissa M Cushing, Shiyong Li
Affiliations

Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia

Brian A Webber et al. Int J Clin Exp Pathol. .

Abstract

The prognostic significance of flow cytometric immunophenotyping (FCI) in acute myeloid leukemia (AML) has been controversial. In this study, we re-investigated the possible role of FCI in the prediction of AML relapse following standard chemotherapy. A total of 209 AML cases with follow-up information were analyzed. Among those, 78 cases were in remission (M:F=44/34; mean age of 48.9 years) and 131 had relapse (M:F=71/60; mean age of 51.3 years). The expression of CD34, HLA-DR or a combination of both was significantly different between the remission and relapse groups for all AML as well as AML without t(15;17). None of the pammyeloid markers or their combinations analyzed was found to correlate with treatment outcomes. Complex cytogenetic abnormalities were more likely associated with relapse group than with remission group, but were not statistically significant after excluding AML with t(15;17). In conclusion, FCI is useful in predicting treatment outcome and disease relapse in AML.

Keywords: Flow cytometric immunophenotyping; acute myeloid leukemia; acute promyelocytic leukemia; chromosome translocation; cytogenetics; prognosis.

PubMed Disclaimer

References

    1. Belov L, de la Vega O, dos Remedios CG, Mulligan SP, Christopherson RI. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res. 2001;61:4483–4489. - PubMed
    1. Bradstock K, Matthews J, Benson E, Page F, Bishop J. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood. 1994;84:1220–1225. - PubMed
    1. Elghetany MT, Sullivan AK, Kurec AS, MacCallum JM, Bloomfield CD, Sobol RE, Davey FR. The use of monoclonal antibodies against primary myeloid granules in normal and leukemic cells. Am J Clin Pathol. 1992;98:430–436. - PubMed
    1. Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C. Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. Ann Hematol. 2007;86:311–327. - PubMed
    1. Harada N, Okamura S, Kubota A, Shimoda K, Ikematsu W, Kondo S, Harada M, Niho Y. Analysis of acute myeloid leukemia cells by flow cytometry, introducing a new light-scattering classification. J Cancer Res Clin Oncol. 1994;120:553–557. - PubMed